Aminosalicylic Acid

DEA Class; Rx

Common Brand Names; Paser

  • 5-Aminosalicylic Acid Derivatives; 
  • Antitubercular Agents

Oral antituberculosis agent that may inhibit folic acid synthesis and/or inhibit synthesis of a cell wall component 
Use second-line to treat tuberculosis infection; often used for multi-drug resistant tuberculosis
Must be used as part of a multi-drug treatment regimen

Indicated for treatment of TB in combination with other active agents; most commonly used in regimens for multi-drug resistant TB or when intolerance to other antitubercular agents occurs

Treatment of mild-to-moderate ulcerative colitis in patients intolerant to sulfasalazine

Hypersensitivity

End-stage renal disease

GI intolerance manifested by nausea, vomiting, diarrhea, and abdominal pain

Hypersensitivity reactions: Fever, skin eruptions of various types, including exfoliative dermatitis, infectious mononucleosis-like, or lymphoma-like syndrome, leucopenia, agranulocytosis, thrombocytopenia, Coombs’ positive hemolytic anemia, jaundice, hepatitis, pericarditis, hypoglycemia, optic neuritis, encephalopathy, Leoffler’s syndrome, vasculitis and a reduction in prothrombin

Crystalluria (prevent by maintaining urine at neutral or alkaline pH)

Monitor liver function; reports of drug-induced hepatitis with rapidly absorbed aminosalicylic acid preparations

Pregnancy Category: C

Lactation: Distributed in human breast milk; caution advised

Adults

12 g/day PO.

Geriatric

12 g/day PO.

Adolescents

300 mg/kg/day (Max: 12 g/day) PO.

Children

300 mg/kg/day (Max: 10 g/day) PO.

Infants

300 mg/kg/day PO.

Neonates

Safety and efficacy have not been established.

Aminosalicylic acid

oral granules, delayed-release

  • 4g/packet

About the Author

You may also like these

0